What's Going On With Pfizer Shares Tuesday?
What's Going On With Pfizer Shares Tuesday?
Pfizer, Inc. (NYSE:PFE) stock is moving slightly higher on Tuesday. The company on Monday reported top-line results of ABRYSVO, a novel vaccine, for respiratory syncytial virus (RSV) in immunocompromised adults.
輝瑞公司（紐交所代碼：PFE）的股票在週二略微上漲。該公司週一公佈了ABRYSVO的頂線結果，這是一種對免疫抑制成年人呼吸道合胞病毒（RSV）的新型生物-疫苗。
What To Know: The results indicated that a single dose of ABRYSVO generates strong neutralizing responses against RSV-A and RSV-B in immunocompromised adults aged 18 and older. In addition, the vaccine was well-tolerated with a safety profile consistent with other studies of the vaccine.
需要知道的是：結果表明，一劑ABRYSVO在免疫功能受損的成年人（18歲及以上）產生了強烈的針對RSV-A和RSV-B的中和反應。此外，該疫苗的耐受性良好，並且安全性與疫苗的其他研究一致。
The results come from Pfizer's substudy B of the Phase 3 MONeT trial which contained 203 immunocompromised adults.
這些結果來自於輝瑞公司第三期MONet試驗的子研究B，該試驗涉及203名免疫功能受損的成年人。
"Immunocompromised adults, such as patients with cancer or autoimmune disorders, have a substantially increased risk of experiencing severe complications from RSV, yet there are currently no vaccines approved for those aged 18 to 59 in the U.S.," said Annaliesa Anderson, senior vice president and chief scientific officer, vaccine research and development, Pfizer.
「免疫功能受損的成年人，例如患有癌症或自體免疫疾病的患者，患RSV的嚴重併發症的風險顯著增加，但目前尚未批准針對美國18至59歲群體的任何疫苗，」輝瑞公司疫苗研究和開發高級副總裁及首席科學官Annaliesa Anderson說道。
"We are encouraged by the positive top-line data from this study, which provide important evidence that ABRYSVO has the potential to address a significant unmet need in this vulnerable population."
「我們對這項研究的積極頂線數據感到鼓舞，這些數據提供了有關ABRYSVO在這種脆弱人群中有可能滿足一項重大未滿足需求的重要證據。」
PFE Price Action: At the time of writing, Pfizer stock is trading 1.32% higher at $28.83, according to data from Benzinga Pro.
PFE價格行情：目前輝瑞公司的股票在Benzinga Pro的數據顯示交易價比之前高1.32美元，股價爲28.83美元。
Image: Photo via Shutterstock
圖像：通過shutterstock拍攝
譯文內容由第三人軟體翻譯。